Baxter International (NYSE:BAX) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Baxter International (NYSE:BAX) released its quarterly earnings results on Thursday. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.06, Zacks reports. The business had revenue of $2.75 billion during the quarter, compared to analysts’ expectations of $2.67 billion. Baxter International had a return on equity of 18.30% and a net margin of 0.77%. Baxter International updated its FY 2025 guidance to 2.450-2.550 EPS and its Q1 2025 guidance to 0.470-0.500 EPS.

Baxter International Price Performance

BAX stock opened at $33.87 on Friday. Baxter International has a 1 year low of $28.33 and a 1 year high of $44.01. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.43 and a quick ratio of 1.09. The stock has a market cap of $17.29 billion, a price-to-earnings ratio of 169.33, a P/E/G ratio of 9.83 and a beta of 0.61. The company has a 50 day simple moving average of $30.65 and a 200 day simple moving average of $34.14.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 2.01%. The ex-dividend date of this dividend is Friday, February 28th. Baxter International’s dividend payout ratio (DPR) is presently 340.02%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on BAX shares. Stifel Nicolaus dropped their price target on Baxter International from $46.00 to $38.00 and set a “buy” rating for the company in a report on Monday, November 11th. Citigroup dropped their price target on Baxter International from $37.00 to $35.00 and set a “neutral” rating for the company in a report on Wednesday, December 11th. JPMorgan Chase & Co. dropped their price target on Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a report on Friday. Barclays assumed coverage on Baxter International in a report on Thursday. They set an “overweight” rating and a $39.00 price target for the company. Finally, StockNews.com cut Baxter International from a “buy” rating to a “hold” rating in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $38.80.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.